BDPTOTCPharmaceutical PreparationsFiscal year ends December 31
BIOADAPTIVES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.00−0.00 (-5.56%)
Close on Oct 19, 2026
- Market cap
- $478.03K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Bioadaptives has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Bioadaptives filed with the SEC
Zeranovia™ Weight Loss Product Shows Promising Results in Dosage Trial
Regulation FD disclosure · EX-99.1 to Form 8-K
BioAdaptives, Inc.’s Board of Directors Approves a One-for-One Stock Dividend
Regulation FD disclosure · EX-99.1 to Form 8-K
BioAdaptives, Inc. Announces Institutional Review Board Approval of a Human Clinical Trial for Zeranovia™
Regulation FD disclosure · EX-99.1 to Form 8-K
BioAdaptives, Inc. Letter to Shareholders
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioAdaptives, Inc. Letter to Shareholders
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioAdaptives, Inc. Appoints James Keener as New CEO to Lead Strategic Growth Initiatives
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K